Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemi-Heart: Gemigliptin vs Glimepiride on Cardiac Function in T2D
NCT05663736Phase 4Unknown
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Jan 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of gemigliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Glycated Hemoglobin at 24 weeks. Status: unknown.
02
Drugs
gemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05663736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663736.